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Although ion channels are increasingly being discovered in cancer cells in vitro
and in vivo, and shown to contribute to different aspects and stages of the cancer
process,much less is known about themechanisms controlling their expression.
Here, we focus on voltage-gatedNaþ channels (VGSCs) which are upregulated
in many types of carcinomas where their activity potentiates cell behaviours
integral to the metastatic cascade. Regulation of VGSCs occurs at a hierarchy
of levels from transcription to post-translation. Importantly, mainstream
cancer mechanisms, especially hormones and growth factors, play a significant
role in the regulation. On the whole, in major hormone-sensitive cancers,
such as breast and prostate cancer, there is a negative association between
genomic steroid hormone sensitivity and functional VGSC expression.
Activity-dependent regulation by positive feedback has been demonstrated in
strongly metastatic cells whereby the VGSC is self-sustaining, with its activity
promoting further functional channel expression. Such auto-regulation is
unlike normal cells in which activity-dependent regulation occurs mostly via
negative feedback. Throughout, we highlight the possible clinical implications
of functional VGSC expression and regulation in cancer.1. Introduction
It is now well established that de novo expression of voltage-gated ion channels
(VGICs) occurs in cancers in vitro and in vivo and plays a significant role in dis-
ease initiation and progression [1–6]. In particular, voltage-gated Naþ channels
(VGSCs) are functionally expressed in many types of carcinomas (cancers of
epithelial origin), including those of breast, cervix, colon, lung (small-cell,
non-small-cell and mesothelioma), skin, ovary and prostate, where they pro-
mote disease progression, potentially leading to metastasis [7]. On the other
hand, voltage-gated Kþ channels (VGPCs) commonly control cellular prolifer-
ation in which VGSC activity plays no role [8,9]. In addition, VGPCs may be
downregulated as cancer becomes more aggressive [2,8]. Such dichotomy in
VGSC–VGPC expression in cancer is consistent with the notion that primary
and secondary tumours are associated with expression of different genes and
can even be controlled independently [10].
Expression and/or activity of VGICs can be regulated from transcription
to post-translation. These include specific mechanisms of post-transcription/
pre-translation, e.g. miRNAs [11] and post-translation, e.g. intracellular traffick-
ing [1,2,6]. The primary regulators include hormones (mainly steroids and
peptides) and growth factors which, in fact, are all intimately associated with
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Figure 1. Schematic diagram of the structure and membrane topology of the voltage-gated sodium channel showing the main regulatory sites. Given a-subunits
have four domains (DI–DIV) each composed of six transmembrane segments. Within the latter, segment four contains positively charged amino acids and this is the
main voltage-sensitive region; the loop between transmembrane segments 5 and 6 is negatively charged and forms the pore region. Many types of modulatory sites
exist for both a- and b-subunits as indicated by the key. The boxes adjacent to a- and b-subunits list the proteins known to interact with each subunit, respect-
ively. PDZ, post-synaptic density protein (PSD95) and Drosophila disc large tumour suppressor (Dlg1) and zonula occludens-1 protein (zo-1); ER, endoplasmic
reticulum; RXR, a motif which mediates retention of proteins in the ER. (Online version in colour.)
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some drugs used for cancer treatment may affect VGICs
[12,13]. Here, we focus on the regulation of VGSCs which
comprise amulti-gene familyof at least nine different functional
members (Nav1.1–1.9) coding for the pore-forming a-subunits
(figure 1) [14]. There are also four auxiliary b-subunits of
which one or two at a time can associate with an a-subunit
and modulate channel expression and activity in plasma
membrane [14].
Several individual Nav isoforms are known to be functio-
nally expressed in different human cancers. These include
Nav1.5 in breast and colon cancers [8,15,16]; Nav1.6 in
cervical cancer [17,18]; and Nav1.7 in breast, prostate and
non-small cell lung cancers [8,19,20]. In addition, where
studied (especially for Nav1.5 and Nav1.7), alternative
splice variants of the isoforms have been found with
sequence differences most notably in the extracellular loop
between segments 3 and 4 of domain I [8,19,21]. At present,
the rationale for such a phenomenon to occur in cancer is
unclear, but consistent with channel expression being both
(i) epigenetic [22] and (ii) oncofetal [23]. The mechanisms
controlling alternative splicing also are not well characterized
but could involve cAMP [24] and activity-dependence [25].
In the case of breast cancer (BCa), the oncofetal/neonatal
isoform of Nav1.5 (nNav1.5) would allow greater Naþ entry
into the cell, compared with the adult splice variant [26]. In
turn, this could have implications for Naþ–Hþ exchangeand intra/extracellular pH regulation [27]; enzyme activity,
e.g. Naþ/Kþ-ATPase and protein kinase A [27,28]; and
Ca2þ homeostasis, e.g. Naþ–Ca2þ exchange [29]. In addi-
tion, the charge-reversing aspartate (negative) to lysine
(positive) amino acid change that occurs at position 211
could affect (i) response to extracellular (intrinsic or extrin-
sic) chemical factors, e.g. pH [30] and (ii) protein–protein
interactions [31].
VGSC activity has been shown to contribute to many cell
behaviours that may be important for metastasis. These
include migration [32–34]; invasion [8,15,16,18,20,34–38];
colony formation in three-dimensional Matrigel [39]; pro-
cess extension [40]; galvanotaxis; [8,41]; adhesion [42];
gene expression [43]; endocytic membrane activity [44–46];
vesicular patterning [47]; nitric oxide production [48]; and
invadopodia formation [49]. Although the mechanisms
underlying the involvement of VGSCs in such cell behaviours
are not well characterized, several suggestions have been
made. These include (i) interaction with cytoskeletal ele-
ments (and/or b-subunits) and (ii) modulation of ion
fluxes/exchangers, gene expression and enzyme activity
[8,18,32,39,49,50]. However, only a few specific mechanisms
have been shown directly to be involved in the proposed
role of VGSCs in metastasis-associated cellular behaviours.
These mechanisms include PKA [51] and Naþ/Hþ exchanger
[39,49]. Importantly, also, SCN5A (the gene that encodes
Nav1.5) was deduced to be upstream of a network of
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Figure 2. Summary diagrams showing possible regulatory pathways controlling voltage-gated sodium channel (VGSC) expression/activity in cells by (a) hormones
and (b) growth factors. Some pathways mediate transcriptional activity; some actions are through the respective receptors, whereas some actions are directly on the
channel. Some of the regulatory pathways have only been described in normal cells. Abbreviations are defined in text. VGSC and VGSC denote decreased and
increased VGSC expression/activity, respectively. (Online version in colour.)
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invasiveness [16]. Thus, VGSCs would appear to play a sig-
nificant role in cancer progression and are a potential novel
therapeutic target against metastasis, the main cause of
death in cancer patients [5,7,8,52].
Our overall approach here is to review, wherever possible,
the available evidence for regulation of VGSC expression/
activity in cancer cells. However, for completeness, we also
cover some essential non-cancer examples.2. Hormones
The development and/or progression of many cancers are
well known to be hormone-dependent; hormone indepen-
dence may develop during treatment, whereupon the
cancer may become more aggressive [53]. Some cancers
show particularly strong hormone sensitivity owing to the
inherent nature of the native tissue, as for BCa and prostate
cancer (PCa) for which oestrogen and androgen are key
steroid hormones, respectively. Consequently, such cancers
are commonly treated with hormone-based medication.
A wide range of signalling mechanisms and cascades are
associated with hormone action upon VGSCs, as illustrated
in figure 2a.
(a) Oestrogen
The effects of b-oestradiol (E2), the biologically active form of
oestrogen, are classically mediated by two types of oestrogenreceptor (ER): ERa and ERb, which belong to the superfamily
of ligand-activated transcription factors (‘nuclear receptors’).
Like other members of this group, ERs function as dimers,
which when bound to their ligand, undergo a translocation
from the cytoplasm to the nucleus where they recognize
specific sequences of DNA-response elements in the promoter
regions of the target genes, ultimately resulting in their up- or
downregulation [54]. However, non-transcriptionmodes of ER
action also occur. Thus, ERa can be localized at the plasma
membrane in multi-protein complexes and mediate fast, non-
genomic effects; several possible variants of such receptors
exist including ER46, ERa-36. In addition, a novel transmem-
brane G-protein-coupled ER (GPER), previously called
‘GPR30’ also mediates fast, non-genomic effects [55].
A basal ‘negative’ association between expression of ERa
and VGSC is apparent in human BCa cells. Thus, the strongly
metastatic MDA-MB-231 cells are devoid of classic ERa, but
express a functional VGSC, in particular nNav1.5 [8]. Conver-
sely, the weakly/non-metastatic MCF-7 cells are ERa-positive
and do not express any functional VGSC [8]. Additional data
were obtained from MDA-MB-231 cells stably transfected
with functional ERa (MDA-MB-231-ERa cells) [56]. In these
cells, compared with controls expressing only the plasmid
vector (VC5), there was a significant decrease in nNav1.5
mRNA levels by 96+2% (figure 3a). Consistent with this,
the proportion of cells expressing functional VGSCs
(nNav1.5) was reduced from 71 to 43% (p, 0.05; n ¼ 10–15
cells) [57]. Furthermore, treatment of the MDA-MB-231-ERa
cells with the ER antagonist ICI-182 780 for more than 48 h
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Figure 3. Effects of oestrogen receptor a (ERa) on voltage-gated sodium channel (VGSC) expression and activity in MDA-MB-231 cells transfected with ERa (MDA-
MB-231-ERa cells). (a) Basal levels of nNav1.5 mRNA were significantly lower in MDA-MB-231-ERa cells (ERa) compared with control cells expressing only the
plasmid vector (VC5; p, 0.001; n ¼ 4). (b) Treatment of MDA-MB-231-ERa cells with the ER antagonist ICI-182,780 (ICI; 1 mM) for more than 72 h significantly
increased the nNav1.5 mRNA level, compared with non-treated cells (Cntl; p , 0.001; n ¼ 4). (c) Similar treatment with ICI-182 780 for more than 48 h signifi-
cantly increased the number of cells with VGSC activity, in comparison with those grown in normal medium (5% FBS–Cntl) as determined by patch-clamp
recording (Fisher’s exact test: p, 0.001; n ¼ 73 cells). (d ) Treatment of MDA-MB-231-ERa cells with ICI-182,780 for more than 72 h significantly increased
the lateral motility of the cells ( p , 0.01; n ¼ 4). Further information is given in the supplementary Methods section.
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mRNA level was increased by 211+49% (figure 3b); (ii) the
proportion of cells expressing functional VGSCs was increased
by more than three-fold (figure 3c); and (iii) the lateral motility
of the cells was increased by 23+5% (figure 3d ).
Taken together, these results suggest that steady-state
VGSC expression is upregulated transcriptionally in the
absence of ERa expression/activity, in general agreement
with ERa-negative (VGSC-expressing) cases of BCa being
more aggressive [58]. Comparable data were obtained from
ERa-knockout mice where mRNA expression of most Nav
isoforms studied was upregulated [59].
However,MDA-MB-231 cells do express a ‘cell-surface’ ER.
Thus, acute (10 s), extracellular application of E2 (10 nM)
increased nNav1.5 current, via GPER coupled to PKA acti-
vation, leading to a reduction in cellular adhesiveness [51].
Acute application of E2 (10 nM) also increased VGSC currentsin rat hypothalamus by a non-genomic mechanism [60]. By
contrast, E2 inhibited VGSC currents in cultured N1E-115
mouse neuroblastoma cells [61]. Similarly, mouse dorsal root
ganglion (DRG) neuronal VGSCs were inhibited by acute
application of E2 and this occurred via a cell-surface ER-
activated protein kinase C (PKC)–PKA pathway [62]. Thus,
the quick effects of E2 on VGSCs may involve different
intracellular signalling cascades, dependent on cell type.
The functional association of ERa/E2 with VGSCs is of
clinical significance, because a significant body of evidence
suggests that clinically prescribed ‘selective oestrogen receptor
modulators’ (SERMs) can also affect VGSCs. Thus, raloxifene
(‘Evista’) inhibited the VGSC current in guinea pig ventricular
myocytes [12]. Tamoxifen also inhibited VGSC activity in the
SHG-44 glioma cell line [13] and in rat cortical neurons [63].
Similar effects of SERMs were seen on rodent hypothalamic
neurons [64] and ventricular myocytes [65].
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effects upon VGSC expression/activity; and (ii) transcription-
ally, E2 (via ERa) downregulates functional VGSC (nNav1.5)
expression in BCa cells. Some of these effects may manifest
clinically in hormone-based treatment of patients and may
impact upon the treatment itself. For example, drug-induced
blockage of VGSCs may impair nerve and/or muscle activity.
More work is needed (i) to generalize these notions; (ii) to
improve our understanding of the role of ERb; (iii) to elucidate
whether the effects differ between cancer and corresponding
normal cells; and (iv) to integrate the fast non-genomic effects
with long-term genomic regulation [66].
(b) Androgen
Two isoforms of androgen receptor (AR) have been identified:
AR-A, a 87-kDa protein with 187 amino acids cleaved from
the amino-terminal domain and AR-B (110 kDa) which is con-
sidered the full-length receptor [54]. Little is known regarding
the effects of androgen on VGSCs in cancer cells. As in the case
of BCa cell lines, however, there is a negative association
between basal expression of AR and VGSC in PCa cell lines.
Thus, VGSC (Nav1.7) activity occurs in strongly metastatic,
AR-devoid PC-3/M cells while AR-expressing, weakly/non-
metastatic LNCaP cells do not possess functional VGSCs
[19]. Application of (5a,17b)-17-hydroxy-androstan-3-one
dihydrotestosterone (DHT) to androgen-deprived LNCaP
cells decreased VGSC b1 mRNA expression over 24–48 h
[67]. Surprisingly, DHT treatment also significantly (but transi-
ently) increased both b1 and Nav1.7 mRNAs in PC-3 cells,
presumably through a non-AR-dependent mechanism [67].
Such an effect could be mediated via a ‘cross-activated’
growth factor receptor signalling cascade [68]. In neuroblastoma
ND7 cells, a nuclear interaction between the developmen-
tally regulated transcription factor Brn-3a and AR resulted
in a complex which bound to multiple elements within the
promoter region of SCN9A (Nav1.7) and upregulated channel
expression [69]. In differentiating mouse muscle C2 cells,
VGSC currents were reduced by androgen treatment and
abolished when AR was overexpressed; there was no change
in VGSC mRNA level, suggesting that the inhibition was
post-transcriptional [70].
In conclusion, from the limited available evidence, the effects
of androgens on VGSC expression/activity appear complex. On
the whole, however, the steady-state association is negative in
PCa (as in BCa), again in line with hormone-insensitive (VGSC-
expressing) cases of PCa being relatively more aggressive.
(c) Other hormones
Several other cancer-associated hormones also affect VGSC
expression/activity. Insulin is a peptide hormone and its recep-
tor (InsR), a tyrosine kinase, can occur in two alternatively
spliced isoforms: InsR-A and InsR-B; the former is the predo-
minant isoform in fetal life and is also the main subtype
expressed in cancer as an ‘oncofetal’ phenomenon [71]. In
InsR-expressing human BCa MDA-MB-231 cells, addition of
insulin (in serum-free medium) increased cellular migration
[72]. Interestingly, blocking VGSC activity by applying tetro-
dotoxin (TTX) in the presence of insulin increased, rather
than decreased, migration implying that insulin additionally
controlled the functional ‘coupling’ between VGSC activity
and the cells’ motility [72]. Insulin has been shown to affect
VGSC expression/activity also in non-cancer cells. In culturedbovine adrenal chromaffin cells, insulin increased cell-surface
expression of VGSC (Nav1.7) and b1 via PI3K; the tran-
scriptional pathway involved phosphorylation of glycogen
synthase kinase-3b (GSK-3b), and downregulation of InsR
substrates 1 and 2 and Akt [73]. In cardiomyocytes, the tran-
scription factor ‘NForkhead box O 1’, which shares
conserved DNA sequences with the insulin responsive
element, regulated Nav1.5 expression by directly binding to
the SCN5A promoter and inhibiting transcriptional activity
[74]. Ion channels may also be modulated by glucocorticoids
[75]. As regards VGSCs, serum- and glucocorticoid-inducible
kinase 1 (SGK1) upregulated Nav1.5 expressed in frog oocytes
[76]. The effect could involve channel phosphorylation and
ubiquitin ligase Nedd4 [76,77]. In addition, although pro-
gesterone was shown to inhibit VGSC currents in cultured
N1E-115 mouse neuroblastoma cells, the high IC50 of this
effect (17 mM) would make the result rather uncertain [61].
The VGSC current in rat striatal neurons was also inhibi-
ted by microM progesterone, and this was thought to occur
via a plasma membrane receptor [78]. It would be worth-
while repeating and extending these experiments, because
progesterone is known to be involved in many cancers [79].3. Growth factors
Growth factors (GFs) are well known to be involved in cancer
initiation and progression [80]. Consequently, GF receptors
and their associated signalling mechanisms are major targets
for cancer therapy [81]. In general, GFs signal via their respect-
ive receptor tyrosine kinases (RTKs) which, in humans,
comprise some 20 subfamilies [80]. Binding of GF activates
an RTK by inducing receptor dimerization, but some may
form oligomers in the absence of the activating ligand [80].
Dimerization results in the activation of the intracellular tyro-
sine kinase domains, in turn, triggering signalling pathways
that can include JAK/STAT, MAP kinase and PI3 kinase [80].
The signalling mechanisms and cascades specifically associ-
ated with GF effects upon VGSCs are summarized in figure 2b.
(a) Epidermal growth factor
Epidermal growth factor (EGF) commonly regulates ion chan-
nel, including VGSC, expression in neurons and muscles [82–
85]. In rat and human PCa cells, EGF upregulated functional
VGSC (Nav1.7) expression which, in turn, promoted motility,
endocytic membrane activity and invasion [86,87]. Similarly,
in human BCa cells, EGF upregulated functional Nav1.5
expression through a PI3K-dependent signalling cascade [88].
In an extensive study on the human non-small-cell lung carci-
noma (NSCLC) cell line H460, EGF upregulated functional
Nav1.7 expression transcriptionally via ERK1/2 and increased
Matrigel invasiveness (figure 4) [89]. Importantly, the EGF-
induced increase in the invasiveness was blocked completely
by silencingNav1.7 expression, i.e. the effect of EGFon invasion
was mediated solely via the channel upregulation [89].
In conclusion, the effects of EGF on carcinoma cell lines
studied to date are consistent with the following basic scheme:
EGF! VGSC upregulation (transcriptional and functional)!
increased metastatic cell behaviours.
(b) Insulin-like growth factor
Incubation of MDA-MB-231 cells for 24 h with AG1024, an
inhibitor of the insulin-like growth factor-1 receptor (IGF-1R)
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In addition, in cultured rat hippocampal neurons, IGF-1 had no
effect on the amplitude of the VGSC currents [91]. However, in
cultured bovine adrenal chromaffin cells, chronic application of
IGF-1 upregulated plasmamembrane expression ofNav1.7; this
was a transcriptional effect involving the PI3K-Akt pathwayand GSK-3b inhibition [92]. Taken together, these findings
suggested a positive feedback loop between Nav1.7 expression
andGSK-3b inhibition. Furtherwork is required (i) to determine
the possible role of IGF-1R signalling in VGSC expression/
activity in cancer cells, and (ii) to elucidate the possible overlap
between the IGF-1R and InsR signalling in this.
Figure 4. (Opposite.) Upregulation of functional expression of Nav1.7 in human non-small-cell lung cancer H460 cells and consequent increase in invasiveness via
ERK1/2 signalling. (a) Current–voltage (I–V) plots for control/untreated cells (open squares) and cells treated in the presence of serum for 24 h with 100 ng ml21
EGF (closed squares), 1 mM gefitinib/Gef (open circles) or 10 mg ml21 EGF receptor blocking antibody ( filled circles). Currents were evoked using 30 ms depolar-
izing steps in 5 mV intervals (290 to þ70 mV) from a holding potential of 290 mV. (b) I–V plots for control/untreated cells (open squares) and cells treated
with 10 mM U0126 (closed squares). (c) Relative Nav1.7 mRNA expression showing effect of serum starvation for 48 h and treatment for 24 h with EGF
(100 ng ml21), Gef (1 mM) and co-application of EGF þ Gef. (d ) Matrigel invasion measured after 48 h in control medium (CTL), 0.5 mM TTX, 100 ng ml21
EGF, 1 mM Gef and EGF þ TTX. (e) Effects of treatment with 10 mM U0126 or 100 nM wortmannin (WORT) for 24 h on relative Nav1.7 mRNA expression, compared
with control/untreated (CTL) cells. ( f ) Matrigel invasion measured over 48 h in control/untreated cells (CTL), and following treatment with 10 mM U0126, 10 mM
U0126/1 mM TTX, 100 nM WORT, and WORT þ TTX. (g) Proposed model for EGF-mediated upregulation of Nav1.7 and consequent invasiveness of H460 cells.
Stimulation of EGFR with EGF results in increased functional expression of Nav1.7 via ERK1/2. Following transcription and translation, the mature Nav1.7 protein
is trafficked to the cell surface where it becomes functional. At the resting membrane potential, VGSCs are partially activated but not fully inactivated, resulting in a
basal influx of Naþ. This increase in [Naþ]i then drives cell invasion through an, as yet, unknown mechanism. All data are presented as means+ s.e. (n ¼ 6–13).
Statistical analyses were with Student’s t-test or one-way ANOVA and Student–Newman–Keuls correction, as appropriate; significance: *p , 0.05, **p, 0.01,
***p, 0.001. Adapted from [89]. (Online version in colour.)
GF1 GF2
VGSC(s)
SH
MCB
Figure 5. A ‘conceptual’ scheme showing how growth factors (GF1, GF2, etc.) and
steroid hormone (SH) signalling systems can feed through and compensate for each
other in regulating expression/activity of the VGSC(s). In turn, VGSC activity
enhances metastatic cell behaviour (MCB). Dotted, horizontal lines denote the inter-
active pathways, involving mostly the intracellular signalling cascades. (Online
version in colour.)
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Long-term (more than 24 h) treatment with nerve growth factor
(NGF) upregulated Nav1.7 functional expression in the strongly
metastatic MAT-LyLu rat PCa cell line; acute application had no
effect [93]. The action of NGF was suppressed by both the pan-
tropomyosin-related receptor tyrosine kinases (Trk) antagonist
K252a, and the PKA inhibitor KT5720, suggesting (i) that it was
receptor mediated, and (ii) that PKAwas a signalling intermedi-
ate [93]. Indeed, the SCN9A promoter in human PCa PC-3 cells
was shown to be activated by NGF [94]. While it appears that
NGF can affect both VGSC expression and cancer cell motility,
further work is required to clarify the connection between the
two effects and the nature of the associated receptor and down-
stream signalling mechanisms. The in vivo relevance of these
findings also remains to be determined. Interestingly, it has
recently been reported that progression of PCa inmice is acceler-
ated by activity in the impinging autonomic nerves [95]. An
intriguing question is whether such activity would release NGF
from the nerves and thus impact upon the cancer VGSCs [96].
(d) Vascular endothelial growth factor
Vascular endothelial growth factor (VEGF) plays a key role in
angiogenesis [97] which also involves invasive cell behaviour
[98]. Not surprisingly, therefore, VEGF has been shown to
affect VGSC expression/activity in several cell types. Thus,
VEGF increased the invasiveness of the cervical cancer cell
line, ME180, by upregulating Nav1.6 expression via p38
MAPK signalling [99]. In human umbilical vein endothelial
cells (HUVECs), VGSC (Nav1.5 and Nav1.7) activity pro-
moted several kinds of angiogenic cell behaviour, including
chemotaxis and tubular differentiation; Nav1.5 potentiated
VEGF-induced ERK1/2 activation through the PKCa-B-Raf
signalling axis, possibly through membrane depolarization,
influx of Naþ, reverse-mode Naþ–Ca2þ exchange and rise in
intracellular Ca2þ [100,101]. In cultured rat hippocampal neur-
ons, VEGF decreased VGSC availability [102], whereas in
bladder DRG neurons, VEGF upregulated VGSC expression
leading to increased excitability [103]. Thus, VEGF can have
mixed effects on VGSC expression/activity in various cell
types, and it would be worthwhile to perform further studies
on cancer cells and cancer-associated endothelia.
(e) Other growth factors
OtherGFs are also associatedwith cancer development and/or
VGSCexpression/activity, and two areworthy of highlighting.Fibroblast growth factors (FGFs) can be classified as secretory
(FGF1–10 and FGF15–23) or intracellular/non-secretory
(FGF11–14) [104]. At present, there are no published data on
the possible effect of FGF(s) on VGSC(s) expressed in cancer
cells. However, work on other cell types suggests that intra-
cellular FGFs co-localize and interact directly with VGSCas
to produce a range of modulatory effects [105,106]. Transform-
ing growth factor-b1 (TGF-b1) is a member of a superfamily of
proteins that includes bone morphogenetic proteins, activins
and inhibins. Activin A increased VGSC currents in the neuro-
blastoma Neuro 2a cell line [107]. In adult cardiomyocytes,
TGF-b1 increased VGSC (Nav1.5) activity and, concomitan-
tly, reduced the outward current [108]. This observation is
reminiscent of the ‘cellular excitability’ hypothesis of cancer
progression, i.e. concurrent upregulation of VGSC and down-
regulation of VGPC activities [2]. However, nearly opposite
effects were seen on neonatal cardiomyocytes [109]. Such con-
trasting effects may be caused, at least partially, by changes in
gene expression during development and may relate to the
oncofetal nature of VGSC expression in cancer. It would be
interesting to test the effects of TGF-b1 on expression/activity
of VGSCs and VGPCs in cancer cells.
In overall conclusion, several GFs can affect VGSC
expression and activity in a variety of cell types, including
cancer and cancer-associated cells. Importantly, the multi-
plicity of GF regulation of VGSCs raises the possibility that
it may be clinically more advantageous to block the VGSC
(the ‘hub’) rather than the individual GF pathways because
the latter can cross-talk (even with hormonal pathways)
and compensate for each other (figure 5) [110,111].
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Figure 6. Activity-dependent regulation of VGSC expression and VGSC-dependent migration. (a) In Mat-LyLu [28] and MDA-MB-231 [34] cells, INa activates adenylate
cyclase (AC) and protein kinase A (PKA), which in turn (i) potentiates a-subunit mRNA expression and (ii) increases channel expression at the plasma membrane,
without affecting total cellular a-subunit protein level. PKA also directly phosphorylates surface-expressed VGSCs, although this may be independent of PKA
(dashed line). Adapted from [28]. (b) Interplay between a and b1 subunits in transcription and process outgrowth, modelled from cerebellar granule neurons.
Trans adhesion between b1 on an adjacent cell and a VGSC signalling complex (comprising a, b1 subunits and contactin), initiates a signalling cascade via FYN
kinase that enhances process outgrowth and migration. Proteolytic processing of b1 by BACE1 and g-secretase is proposed to release the soluble intracellular
domain of b1, which may in turn enhance transcription of a subunit genes. Nav1.6 activity is required for b1-mediated process outgrowth, and in turn, b1 is required
for normal localization of a-subunits. Thus, INa may fine-tune the dual processes of gene expression and migration. Adapted from [117]. (Online version in colour.)
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Auto-regulation of VGSCs may occur in either of two ways:
dependent upon channel activity and association with b1
subunits.(a) Activity-dependent regulation
Activity-dependent regulation of ion channel function is well
known to occur in the central nervous system and is critical
for correct neuronal development, wiring and plasticity
[112]. In particular, expression of neuronal VGSCa is often
regulated by negative feedback, such that patterned activity
or chronic treatment with VGSC openers leads to reduction
of mRNA/protein expression and change in the balance of
intracellular trafficking in favour of channel internalization
[113–115]. Conversely, treatment with VGSC blockers
increases functional protein expression at the plasma mem-
brane [116]. Thus, steady-state VGSC expression is normally
tightly regulated in order to optimize activity and avoid
hyper-excitability.
Notably, however, a different situation appears to exist in
cancer cells. In strongly metastatic rat PCa MAT-LyLu cells,
expression of Nav1.7 was found to be maintained by positive
feedback [28]. Thus, chronic pre-treatment of MAT-LyLu cells
with TTX inhibited the VGSC current (INa) which persisted
after drug washout; this suppression could be reversed with
theNaþ ionophoremonensin, implying that a rise in intracellu-
lar Naþ was involved. In addition, TTX reduced PKA
phosphorylation, and the PKA inhibitor KT5720 also reduced
INa, whereas the adenylate cyclase (AC) activator forskolin
increased INa, suggesting that the positive feedbackmechanism
is dependent on AC/PKA (figure 6a) [28,118,119]. A similar
mechanism of auto-regulation was found for nNav1.5
expression in human metastatic BCa MDA-MB-231 cells [34].
Importantly, pre-treatment with TTX eliminated the VGSC-
dependent migration in MAT-LyLu cells [28], and suppressedboth basal and PKA-induced migration and invasion in
MDA-MB-231 cells [34]. These results suggested that inhibition
of INawould collapse the positive feedback loop, whichwould,
in turn, reduce the cells’ migratory and invasive capacity.
Indeed, it is well established that it is the influx of Naþ through
VGSC that is essential for invasion [8,20,39]. In both BCa and
NSCLC cell lines, the partial opening of VGSC at the resting
membrane potential, Vm, allows tonic Na
þ influx, which in
turn keeps Vm sufficiently depolarized to maintain a small
but continuous influx of Naþ [20,39,89]. Thus, under the ensu-
ing pathophysiological conditions, Naþ influx is sufficient to
maintain the positive feedback and the invasive capability of
cancer cells.
These data therefore suggest that in metastatic carcinoma
cells, VGSCa expression is at minimum self-sustaining, and
thus may potentiate metastasis in persistent fashion. The
results also raise the possibility that chronic blockage of
VGSCs would suppress both channel activity and expression
and, consequently, provide a dual advantage in any clinical
anti-metastatic treatment.
(b) VGSC b1 subunit
Downstream functions of theVGSCb1 subunit, which is both a
channel modulator and a cell adhesion molecule, may also be
regulated in part by INa and this interaction may be reciprocal
[120]. In BCa MCF-7 cells, b1 downregulation with siRNA
reduced cellular adhesion to substrate and increased VGSC-
dependent migration [121]. However, TTX had no effect on
basal b1 subunit mRNA levels, consistent with lack of func-
tional VGSC activity in these weakly/non-metastatic cells
[121]. By contrast, the reverse could occur. Thus, downregulat-
ing SCN1B with siRNA upregulated nNav1.5 mRNA and
protein expression [121]. It appeared that putting the cells
into a higher metastatic mode by reducing their substrate
adhesion automatically upregulated the VGSC expression.
Such reciprocal expression of endogenous b1 and Nav1.7 has
rstb.royalsocietypublishing.or
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b1 alone by siRNA was sufficient to cause a modest (approx.
30%) enhancement of A549 cell invasion, whereas overexpres-
sion of exogenous b1 reduced H460 cell invasion to a similar
extent [89]. Thus, the VGSC b1 subunit has a multi-functional
role in cancer and appears to be involved in a complex feedback
loop that regulates channel expression/function [117]. In turn,
this would modulate adhesion-mediated functions of the b1
subunit, including cellular process extension and invasiveness
(figure 6b). g
Phil.Trans.R.Soc.B
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The idea that VGSCs are expressed during cancer progression
and that VGSC activity enhances cell behaviours linked to
metastasis, such as motility, invasion and adhesion, is now
well-established. There is increasing evidence, as highlighted
here, that such VGSC expression is under the control of ‘main-
stream’ cancer mechanisms, principally hormones and growth
factors, thus placing VGSCs as key regulators in cancer pro-
gression. However, other messenger molecules, including
immunemodulators, can also affect channel expression/activity
[122]. Although regulation ofVGSCs in cancer occurs clearlyat a
hierarchy of levels from transcription to post-translation, much
work remains to determine the precise mechanisms involved.Regarding the former, developmentally regulated transcription
factors, such as REST (‘neuron-specific silencing factor’), are
also known to affect both the cancer process and channel
expression [84].
It may be possible in the future, therefore, to combine
conventional (e.g. hormone-based) therapies with clinically
viable VGSC blockers. This may even help alleviate some of
the problems associated with hormone-based therapies such
as the insensitivity that frequently ensues in such treatments.
Importantly, there are some indications that VGSC regulation
may differ between ‘cancer’ and ‘normal’ cells. If so, under-
standing the signalling pathways that regulate VGSC
expression/activity in cancer may provide additional ave-
nues for preventing or suppressing metastatic disease.
Furthermore, a newly discovered ‘non-canonical’ role of
intracellular VGSCs in cell behaviour warrants investigation
in the context of cancer [123]. In fact, a systematic analysis
of the whole interactive network of ion channels and trans-
porters is required ultimately in order to gain an overall
and precise understanding of the role of ionic activity in
cancer and to exploit this knowledge clinically.
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